Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 12

1.

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr.

Hum Mol Genet. 1993 Jul;2(7):851-6.

PMID:
8103403
2.

Pheochromocytoma penetrance varies by RET mutation in MEN 2A.

Quayle FJ, Fialkowski EA, Benveniste R, Moley JF.

Surgery. 2007 Dec;142(6):800-5; discussion 805.e1. Epub 2007 Nov 5. Erratum in: Surgery. 2008 Feb;143(2):301.

PMID:
18063059
3.

The risk of medullary thyroid carcinoma in patients with Hirschsprung's disease.

Skába R, Dvoráková S, Václavíková E, Vlcek P, Frantlová M, Bendlová B.

Pediatr Surg Int. 2006 Dec;22(12):991-5.

PMID:
17021738
4.

Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene.

Mulligan LM, Eng C, Attié T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, et al.

Hum Mol Genet. 1994 Dec;3(12):2163-7.

PMID:
7881414
5.

Clinical presentations and RET protooncogene mutations in seven multiple endocrine neoplasia type 2 kindreds.

Blank RD, Sklar CA, Dimich AB, LaQuaglia MP, Brennan MF.

Cancer. 1996 Nov 1;78(9):1996-2003.

PMID:
8909322
6.

Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease.

Arighi E, Popsueva A, Degl'Innocenti D, Borrello MG, Carniti C, Perälä NM, Pierotti MA, Sariola H.

Mol Endocrinol. 2004 Apr;18(4):1004-17. Epub 2004 Jan 8.

PMID:
14715928
7.

Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.

Chappuis-Flament S, Pasini A, De Vita G, Ségouffin-Cariou C, Fusco A, Attié T, Lenoir GM, Santoro M, Billaud M.

Oncogene. 1998 Dec 3;17(22):2851-61.

8.
9.

Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.

Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, Toledo SP, Toledo RA, Tavares MR, Alevizaki M, Mian C, Siggelkow H, Hüfner M, Wohllk N, Opocher G, Dvořáková S, Bendlova B, Czetwertynska M, Skasko E, Barontini M, Sanso G, Vorländer C, Maia AL, Patocs A, Links TP, de Groot JW, Kerstens MN, Valk GD, Miehle K, Musholt TJ, Biarnes J, Damjanovic S, Muresan M, Wüster C, Fassnacht M, Peczkowska M, Fauth C, Golcher H, Walter MA, Pichl J, Raue F, Eng C, Neumann HP; International RET Exon 10 Consortium.

Hum Mutat. 2011 Jan;32(1):51-8. doi: 10.1002/humu.21385.

PMID:
20979234
10.

Familial associations in medullary thyroid carcinoma with Hirschsprung disease: the role of the RET-C620 "Janus" genetic variation.

Moore SW, Zaahl M.

J Pediatr Surg. 2010 Feb;45(2):393-6. doi: 10.1016/j.jpedsurg.2009.10.080.

PMID:
20152359
11.

RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype.

Pinna G, Orgiana G, Riola A, Ghiani M, Lai ML, Carcassi C, Mariotti S.

Thyroid. 2007 Feb;17(2):101-4.

PMID:
17316110
12.

Acceptable age for prophylactic surgery in children with multiple endocrine neoplasia type 2a.

Kahraman T, de Groot JW, Rouwe C, Hofstra RM, Links TP, Sijmons RH, Plukker JT.

Eur J Surg Oncol. 2003 May;29(4):331-5.

PMID:
12711285

Supplemental Content

Support Center